<DOC>
	<DOCNO>NCT01122888</DOCNO>
	<brief_summary>This clinical trial study well give cilengitide together sunitinib malate work treat patient advance solid tumor glioblastoma multiforme . Cilengitide sunitinib malate may stop growth tumor cell block blood flow tumor . Giving cilengitide together sunitinib malate may kill tumor cell . Studying sample blood laboratory patient receive cilengitide sunitinib malate may help doctor understand effect drug biomarkers .</brief_summary>
	<brief_title>Cilengitide Sunitinib Malate Treating Patients With Advanced Solid Tumors Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine effect cilengitide change serum VEGFR2 , pharmacodynamic biomarker sunitinib malate effect endothelial function , withdrawal phase course sunitinib malate patient advance solid tumor glioblastoma multiforme . SECONDARY OBJECTIVES : I . Determine effect cilengitide exposure change VEGFR2 14-day interval end sunitinib malate administration end course 1 patient . II . Test safety efficacy regimen patient . III . Develop serum collagen c-telopeptide crosslinks ( CTx ) pharmacodynamic marker cilengitide . OUTLINE : COURSE I : Patients receive oral sunitinib malate day 1-14 ( week 1-2 ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive cilengitide IV 1 hour twice week 3 4 . ARM II : Patients receive treatment week 3 4 . COURSE II : Patients arm receive oral sunitinib malate day 1-14 cilengitide IV 1 hour twice week 3 4 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirm solid tumor malignant glioblastoma multiforme meeting &gt; = 1 follow criterion : Disease refractory standard therapy No standard therapy exist Sunitinib malate monotherapy would appropriate management Measurable disease require Previously treat brain metastasis primary brain neoplasm allow provided patient receive concurrent corticosteroid Karnofsky performance status 70100 % Absolute neutrophil count ( ANC ) &gt; = 1,500/μL White blood cell count ( WBC ) &gt; = 3,000/μL Platelet count &gt; = 100,000/μL Hemoglobin &gt; = 9 g/dL Total bilirubin normal ( unless due document Gilbert syndrome ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 time upper limit normal ( ULN ) ( &lt; 5 time ULN presence liver metastasis ) Creatinine normal OR creatinine clearance &gt; = 60 mL/min Serum calcium = &lt; 12.0 mg/dL QTc &lt; 500 msec Patients follow allow provided New York Heart Association ( NYHA ) class III cardiac function undergo baseline echocardiogram ( ECHO ) /multiple gated acquisition ( MUGA ) : History class II heart failure asymptomatic treatment Prior anthracycline exposure Previously treat central thoracic radiotherapy include heart radiotherapy port Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No history allergic reaction attribute compound similar chemical biologic composition sunitinib malate No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness and/or social situation would limit compliance study requirement No preexist thyroid abnormality thyroid function maintain normal range medication No document thrombosis ( pulmonary embolism deep vein thrombosis ) within past 6 month No know coagulopathy thrombophilia No proven gastric duodenal ulcer clinically significant gastrointestinal ( GI ) blood loss within past 6 week No history central nervous system ( CNS ) hemorrhage No lifethreatening bleed diathesis within past 6 month No history serious ventricular arrhythmia ( i.e. , ventricular fibrillation ventricular tachycardia &gt; = 3 beat row ) significant electrocardiogram ( ECG ) abnormalities No poorly control hypertension ( i.e. , systolic blood pressure ( BP ) &gt; = 150 mm Hg diastolic BP &gt; = 100 mm Hg ) No condition would impair ability swallow retain sunitinib malate tablet , include follow : GI tract disease result inability take oral medication requirement IV alimentation Prior surgical procedure affect absorption Active peptic ulcer disease No gastrostomy , jejunostomy , form enteral tube feed modality None follow condition : Serious nonhealing wound ulcer Abdominal fistula , GI perforation , intraabdominal abscess within past 28 day Cerebrovascular accident transient ischemic attack within past 12 month Myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within past 12 month NYHA class III IV heart failure Radiographically physiologically diagnose usual interstitial pneumonitis ( UIP ) nonspecific interstitial pneumonitis ( NSIP ) No bone fracture within past 12 month No concurrent anticancer agent therapies More 4 week since prior radiotherapy systemic antineoplastic therapy ( 6 week nitrosoureas , mitomycin C , bevacizumab ) recover More 2 week since prior hormone replacement therapy hormonal contraceptive More 1 month since prior surgery At least 7 day since prior concurrent CYP3A4 inhibitor At least 12 day since prior concurrent CYP3A4 inducer Prior luteinizing hormonereleasing hormone agonist hormonerefractory prostate cancer allow Prior antiangiogenic agent ( e.g. , sorafenib , pazopanib , AZD2171 [ cediranib maleate ] , PTK787 [ vatalanib ] , VEGF Trap [ zivaflibercept ] ) allow provided disease progression No prior cilengitide sunitinib malate No prior bevacizumab No concurrent investigational agent No concurrent combination antiretroviral therapy human immunodeficiency virus ( HIV ) positive patient No concurrent agent proarrhythmic potential ( e.g. , terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide , flecainide ) No concurrent palliative radiotherapy No concurrent chemotherapy biologic agents No concurrent medication may cause QTc prolongation No concurrent therapeutic dos coumarinderivative anticoagulant ( e.g. , warfarin ) Up 2 mg daily warfarin prophylaxis thrombosis allow Lowmolecular weight heparin allow provide prothrombin time ( PT ) /international normalize ratio ( INR ) = &lt; 1.5 No concurrent grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>